Bristol-Myers Squibb Co’s filing revealed that its SVP and Controller Holzer Phil M unloaded Company’s shares for reported $38930.0 on Nov 04 ’24. In the deal valued at $55.62 per share,700 shares were sold. As a result of this transaction, Holzer Phil M now holds 11,760 shares worth roughly $0.69 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Hirawat Samit bought 1,830 shares, generating $100,055 in total proceeds. Upon buying the shares at $54.67, the EVP,Chief Med.Offr.,Drug Dev. now owns 62,109 shares.
Before that, Holzer Phil M bought 700 shares. Bristol-Myers Squibb Co shares valued at $38,930 were divested by the Officer at a price of $55.62 per share.
Wolfe Research initiated its Bristol-Myers Squibb Co [BMY] rating to a Peer perform in a research note published recently. A number of analysts have revised their coverage, including Daiwa Securities’s analysts, who increased its forecast for the stock in mid November from “a Neutral” to “an Outperform”. Leerink Partners also remained covering BMY and has increased its forecast on November 12, 2024 with a “an Outperform” recommendation from previously “Market perform” rating. Citigroup revised its rating on October 25, 2024. It rated BMY as “a Neutral” which previously was an “a Buy”.
Price Performance Review of BMY
On Monday, Bristol-Myers Squibb Co [NYSE:BMY] saw its stock fall -1.13% to $58.71. Over the last five days, the stock has lost -2.05%. Bristol-Myers Squibb Co shares have risen nearly 14.42% since the year began. Nevertheless, the stocks have risen 17.05% over the past one year. While a 52-week high of $61.08 was reached on 11/11/24, a 52-week low of $39.35 was recorded on 07/05/24. SMA at 50 days reached $55.46, while 200 days put it at $48.98.
Levels Of Support And Resistance For BMY Stock
The 24-hour chart illustrates a support level at 58.35, which if violated will result in even more drops to 58.00. On the upside, there is a resistance level at 59.41. A further resistance level may holdings at 60.12. The Relative Strength Index (RSI) on the 14-day chart is 56.69, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.18, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 42.97%. Stochastics %K at 64.10% indicates the stock is a holding.
How much short interest is there in Bristol-Myers Squibb Co?
A steep rise in short interest was recorded in Bristol-Myers Squibb Co stocks on 2024-11-15, growing by 3.27 million shares to a total of 25.77 million shares. Yahoo Finance data shows the prior-month short interest on 2024-10-15 was 22.5 million shares. There was a rise of 12.7%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on October 17, 2024 when Bernstein began covering the stock and recommended ‘”a Mkt perform”‘ rating along with a $56 price target.
